Veea signs non-binding term sheet to combine with NovaGen; $10M cornerstone investment from GeoNova

VEEA INC.

Veea (NASDAQ: VEEA) signed non-binding term sheet with NovaGen Group B.V. for proposed business combination; definitive agreement targeted within weeks.
Combined company valued at approximately $750 million based on internal projections and independent valuation; GeoNova Capital commits initial $10M.
NovaGen Health Networks platform integrating Veea's edge AI infrastructure with NovaGen's cellular reprogramming science; initial deployments at NovaGen clinics and partner hospitals in Q4 2026.
Transaction subject to definitive agreements, due diligence (incl. IP and valuation), shareholder and regulatory approvals; no assurance of consummation.
Two-phase rollout: Phase 1 (Q4 2026) household health hub with digital twin; Phase 2 clinician-supervised diagnostics and therapy pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.